These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31124219)

  • 1. Suppression of epidermal growth factor receptor-mediated β-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
    Niu J; Wang X; Liang C; Zhang YD; Liu FY; Li HY; Xie SQ; Sun H; Fang D
    Cell Biol Int; 2019 Aug; 43(8):931-939. PubMed ID: 31124219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
    Li P; Torossian A; Zhang Q; Xu WC; Fu S
    Med Oncol; 2012 Dec; 29(5):3258-64. PubMed ID: 22729368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation.
    Li W; Hou JZ; Niu J; Xi ZQ; Ma C; Sun H; Wang CJ; Fang D; Li Q; Xie SQ
    Cell Commun Signal; 2018 Nov; 16(1):82. PubMed ID: 30445978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.
    Ren Y; Zhou X; Qi Y; Li G; Mei M; Yao Z
    Oncol Rep; 2012 Sep; 28(3):943-8. PubMed ID: 22710837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
    Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation.
    Zhao Y; Ge CC; Wang J; Wu XX; Li XM; Li W; Wang SS; Liu T; Hou JZ; Sun H; Fang D; Xie SQ
    Oncol Rep; 2017 Nov; 38(5):3055-3063. PubMed ID: 29048617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
    Meng X; Hu B; Hossain MM; Chen G; Sun Y; Zhang X
    Int J Oncol; 2016 Aug; 49(2):682-90. PubMed ID: 27221510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231).
    Elumalai P; Arunkumar R; Benson CS; Sharmila G; Arunakaran J
    Cell Biochem Funct; 2014 Jul; 32(5):476-84. PubMed ID: 24888707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
    Xie X; Tang B; Zhou J; Gao Q; Zhang P
    Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
    Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N
    Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells.
    Kurrle N; Ockenga W; Meister M; Völlner F; Kühne S; John BA; Banning A; Tikkanen R
    BMC Cancer; 2013 Dec; 13():575. PubMed ID: 24304721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis.
    Chen J; Wang W; Wang H; Liu X; Guo X
    Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the PI3K/Akt/mTor pathway using
    Phyu SM; Tseng CC; Fleming IN; Smith TA
    Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.